Platelet-derived growth factor receptor tyrosine kinase inhibitors: a review of the recent patent literature
Explore this paper's citation graph
Summary
This review surveys the small molecule PDGFR inhibitors reported in patent literature over the past 5 years and offers an overview of the chemical scaffolds and the activity/selectivity of the newly discovered PDG FR inhibitors.
- Type
- review
- Published
- 2010-06-16
- Cited by
- 35
- References
- 63
- OpenAlex
- https://openalex.org/W2004431239
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:33199865
Keywords
Platelet-derived growth factor receptor, Sunitinib, Tyrosine kinase, Growth factor receptor, Platelet-derived growth factor
References
- Autophosphorylation of the PDGF receptor in the kinase insert region regulates interactions with cell proteins.
- Imatinib mesylate in advanced dermatofibrosarcoma protuberans: pooled analysis of two phase II clinical trials.
- Atherosclerosis is an Inflammatory Disease
- Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor
- Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy.
- Involvement of platelet-derived growth factor in disease: development of specific antagonists.
- Platelet-derived growth factor (PDGF) stimulates PDGF receptor subunit dimerization and intersubunit trans-phosphorylation.
- Platelet-derived growth factor and its receptors in human glioma tissue: expression of messenger RNA and protein suggests the presence of autocrine and paracrine loops.
- What brings pericytes to tumor vessels?
- Design, structure-activity relationships and in vivo characterization of 4-amino-3-benzimidazol-2-ylhydroquinolin-2-ones: a novel class of receptor tyrosine kinase inhibitors.
- Imatinib mesylate inhibits the profibrogenic activity of TGF-beta and prevents bleomycin-mediated lung fibrosis.
- From magic bullets to designed multiple ligands.
- Treatment with imatinib prevents fibrosis in different preclinical models of systemic sclerosis and induces regression of established fibrosis.
- Human breast carcinoma desmoplasia is PDGF initiated
- Regulation of PDGF and its receptors in fibrotic diseases.
- Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays.
- Endothelial and nonendothelial sources of PDGF-B regulate pericyte recruitment and influence vascular pattern formation in tumors.
- Tumorigenic conversion of immortal human keratinocytes through stromal cell activation.
- Dual inhibition of c‐abl and PDGF receptor signaling by dasatinib and nilotinib for the treatment of dermal fibrosis
- Discovery of N-(4-(3-amino-1H-indazol-4-yl)phenyl)-N'-(2-fluoro-5-methylphenyl)urea (ABT-869), a 3-aminoindazole-based orally active multitargeted receptor tyrosine kinase inhibitor.
Cited by
- Regulation of EGFR Degradation by Ankyrin105
- Design of kidney-targeted drug-carrier conjugates for the inhibition of profibrotic signaling cascades
- The impact of chromosome 17p alterations on cancer
- An Omics Perspective on Molecular Biomarkers for Diagnosis, Prognosis, and Therapeutics of Cholangiocarcinoma
- Adenosine monophosphate-activated protein kinase regulates platelet-derived growth factor-BB-induced vascular smooth muscle cell migration.
- Candidate genes involving in tumorigenesis of cholangiocarcinoma induced by Opisthorchis viverrini infection
- PDGFRA promoter polymorphisms are associated with the risk of papillary thyroid cancer.
- Phase I study of olaratumab in Japanese patients with advanced solid tumors
- Distinct Phenotypic Differences Associated with Differential Amplification of Receptor Tyrosine Kinase Genes at 4q12 in Glioblastoma
- Overexpression of PDGFA and its receptor during carcinogenesis of Opisthorchis viverrini-associated cholangiocarcinoma.
- Discovery of a Novel Class of Imidazo[1,2-a]Pyridines with Potent PDGFR Activity and Oral Bioavailability.
- A phase I study of olaratumab, an anti-platelet-derived growth factor receptor alpha (PDGFRα) monoclonal antibody, in patients with advanced solid tumors
- Colorimetric detection of platelet-derived growth factors through competitive interactions between proteins and functional gold nanoparticles.
- Targeting the PDGF Signaling Pathway in the Treatment of Non-Malignant Diseases
- MiR-128, a key regulator of oncogenic properties
- Cytogenetics and genetics of human cancer: methods and accomplishments.
- Anti-fibrotic Activity and Enhanced Interleukin-6 Production by Hepatic Stellate cells in Response to Imatinib Mesylate
- Mutant p53 drives pancreatic cancer metastasis through cell-autonomous PDGF receptor beta signaling
- PDGF-α stimulates intestinal epithelial cell turnover after massive small bowel resection in a rat.
- Computational prediction of formulation strategies for beyond-rule-of-5 compounds.
Related papers
- Future options for imatinib mesilate-resistant tumors
- Activity of tyrosine kinase inhibitors in multiple myeloma
- Data from Comparison of antitumor effects of multitargeted tyrosine kinase inhibitors in acute myelogenous leukemia
- Platelet-derived growth factor receptor/platelet-derived growth factor (PDGFR/PDGF) system is a prognostic and treatment response biomarker with multifarious therapeutic targets in cancers
- Gastrointestinal stromal tumours and their response to treatment with the tyrosine kinase inhibitor imatinib
- Combinatorial treatment of malignant peripheral nerve sheath tumors with tyrosine kinase inhibitors hinders proliferation and survival
- Role of KIT and platelet-derived growth factor receptors as oncoproteins.
- [Molecular mechanism and therapeutic strategy for resistance to tyrosine kinase inhibitors in targeted treatment of gastrointestinal stromal tumors].